Chemotherapy based combinations in AML: Time to take a step back?

Complete remissions (CR) are documented in most, but not all, patients with AML deemed eligible for induction chemotherapy (CR rates>75% in patients younger than 60 years and>50% in patients older than 60 years). [1] Unfortunately, the majority of patients relapse within 3 years after achieving a CR and relapsed AML remains the most common cause of AML-related mortality. Thus, for patients with primary refractory and/or relapsed AML, resistance to chemotherapy, including cytarabine, remains a major clinical obstacle.

Source: Leukemia Research - August 31, 2018 Category: Hematology Authors: Bruno C. Medeiros Source Type: research